-
2 months ago | 
outsourcedpharma.com | Louis Garguilo |Emerging trends |Bikash Chatterjee |Pharmatech Associates
Are you attending World ADC London this year? On March 4th, don't miss our presentation on "Technical Excellence in Development and Manufacturing of Bioconjugates". Visit booth #10 to meet our team and discover how we can accelerate your ADC, bioconjugate, or small molecule conjugate program. Request a meeting to discuss your needs with our experts and discover how we can support you with our 15+ years of experience and leading expertise in contract development and manufacturing.
-
2 months ago | 
outsourcedpharma.com | Bikash Chatterjee |Pharmatech Associates |Louis Garguilo
By Bikash Chatterjee, CEO, Pharmatech Associates
The biopharma industry’s clinical pipeline is reaching its largest and most diverse in history.
-
Jun 19, 2024 | 
outsourcedpharma.com | Louis Garguilo |Fred A. Rowley |Bikash Chatterjee |Pharmatech Associates
Webinar: You Had Me at Flow: The Shift from Batch to Continuous A clear increase in continuous flow processes has emerged over the past decade thanks to the commercialization of preparative flow reactor units. This need for continuous flow manufacturing of active pharmaceutical ingredients and fine chemicals continues to grow as it offers important advantages over traditional batch manufacturing in terms of quality, safety, and sustainability of the overall process. Click here to learn more.
-
Jun 7, 2024 | 
cellandgene.com | Emily Marden |Kelly Kasulis Cho |Bikash Chatterjee |Pharmatech Associates
With additional cell therapy approvals on the horizon, a diverse array of products and platforms are needed to ensure safety and efficacy in manufacturing, increase speed to market, and decrease overall COGS. Join Cell & Gene Live for a digital discussion on the next generation of platforms and innovative technologies. Registration is free thanks to the support of Invetech. Hello Cell & Gene readers,I'm happy to bring you May's most-clicked articles.
-
Mar 25, 2024 | 
cellandgene.com | Shalini Nagar |Bikash Chatterjee |Pharmatech Associates
Stem cells are the backbone of many allogeneic therapies and where they come from affects development and supply chain logistics, particularly cryopreservation. What temperatures are ideal to maintain product potency? How do you build a reliable cold chain? How do you work with existing infrastructure to allow for an “off-the-shelf” therapy? Don’t miss the next Cell & Gene Live digital event! Registration is free thanks to the support of Charter Medical and Bio-Techne.
-
Feb 14, 2024 | 
bioprocessonline.com | Guriqbal Singh |Bikash Chatterjee |Pharmatech Associates
A Polishing Strategy For Removing Impurities In Bispecific Antibody PurificationBispecific antibodies (bsAbs) are therapeutically promising due to their ability to bind to two different antigens. In this webcast, we demonstrate a polishing strategy using CHT™ Ceramic Hydroxyapatite media. The study achieved excellent removal of byproducts and impurities in a single chromatographic step, yielding purified products with low HCP contents and HCDNA levels.
-
Oct 15, 2023 | 
pharmtech.com | Bikash Chatterjee
Published on: Pharmaceutical Technology, Trends in Formulation, October 2023 eBook, Volume 2023 eBook, Issue 5Pages: 34-44CPHI’s Annual Report predicts huge impact of AI on drug development and manufacturing. Healthcare technology, Medical revolution and the advance of technology Artificial Intelligence, AI Deep Learning for Medical Research, Transformation of innovation and technology for future Health.
-
Oct 2, 2023 | 
bioprocessonline.com | Bikash Chatterjee |Pharmatech Associates
By Bikash Chatterjee, Chief Executive Officer, Pharmatech Associates
Originally published by PharmaManufacturing.com, October 2022.
Two decades ago, the predominant perception was that pharma manufacturing and quality sensibilities were better suited to batch manufacturing. The volumes of most pharmaceutical products were much smaller than chemical processes — an industry in which continuous manufacturing was broadly used — making batch processes more suitable for pharma operations.
-
Sep 26, 2023 | 
ecmconnection.com | Bikash Chatterjee |Pharmatech Associates
By Bikash Chatterjee, Chief Executive Officer, Pharmatech Associates
VIEW THE WHITE PAPER!
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of ECM Connection? Subscribe today.
-
Sep 26, 2023 | 
outsourcedpharma.com | Bikash Chatterjee |Pharmatech Associates |Louis Garguilo
By Bikash Chatterjee, Chief Executive Officer, Pharmatech Associates
Originally published by PharmaManufacturing.com, October 2022.
Two decades ago, the predominant perception was that pharma manufacturing and quality sensibilities were better suited to batch manufacturing. The volumes of most pharmaceutical products were much smaller than chemical processes — an industry in which continuous manufacturing was broadly used — making batch processes more suitable for pharma operations.
